Search Result

Results for "

CNS cancers

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Antibiotic (1) Apoptosis (3) Bacterial (1) c-Fms (2) c-Kit (1) CDK (1) EGFR (1) Endogenous Metabolite (2) Epigenetic Reader Domain (1) Ferroptosis (2) HDAC (1) HIV (1) iGluR (2) JNK (1) Monoamine Oxidase (1) PI3K (1) PKC (1) Raf (1) Sodium Channel (2) Somatostatin Receptor (2) Topoisomerase (2) VEGFR (3) Virus Protease (1)
By Research Areas:	Cancer (21) Cardiovascular Disease (2) Infection (4) Inflammation/Immunology (2) Neurological Disease (11)
Oligonucleotides:	Fillers (1)

Inhibitors & Agonists

Natural
Products

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B0653A

Levobupivacaine hydrochloride 2 Publications Verification (S)-(-)-Bupivacaine monohydrochloride	Sodium Channel Ferroptosis	Cardiovascular Disease Neurological Disease Cancer
Levobupivacaine hydrochloride ((S)-(-)-Bupivacaine monohydrochloride) is a long-acting amide local agent that can suppress or relieve pain. Levobupivacaine hydrochloride exerts agent that can suppress or relieve pain. and analgesic effects through reversible blockade of neuronal sodium channel. Levobupivacaine hydrochloride can inhibit impulse transmission and conduction in cardiovascular and other tissues, possessing certain cardiac and CNS toxicity. Levobupivacaine hydrochloride is metabolized by hepatic cytochrome P450 (CYP450) enzymes in vivo. Levobupivacaine hydrochloride can also induce ferroptosis by miR-489-3p/SLC7A11 signaling in gastric cancer .

HY-156681

STX-478	PI3K	Cancer
STX-478 (compound 80) is an oral CNS-penetrant allosteric mutant-selective PI3Kα inhibitor. STX-478 shows robust and durable tumor regression and can be used in cancer research .

HY-164307

Pebezertinib BLU 451; LNG-451	EGFR	Cancer
Pebezertinib (BLU 451) is an orally active inhibitor for EGFR. Pebezertinib exhibits the ability to penetrate the central nervous system (CNS). Pebezertinib can be used for research about non-small cell lung cancer carrying EGFR exon 20 insertion .

HY-163806

NT376	HDAC	Neurological Disease Cancer
NT376 is a high potency and selectivity inhibitor of class-IIa Histone deacetylases (HDAC) with an IC₅₀ value of 32 nM, similar to NT160 (HY-149285) (IC₅₀= 46 nM) in HT-29 cells. NT376 is proming for research of various cancers and in the diseases of the central nervous system (CNS) such as Alzheimer’s and Huntington’s diseases .

HY-B0653

Levobupivacaine (S)-(-)-Bupivacaine	Sodium Channel Ferroptosis	Neurological Disease Cancer
Levobupivacaine ((S)-(-)-Bupivacaine) is a long-acting amide local agent that can suppress or relieve pain. Levobupivacaine exerts agent that can suppress or relieve pain. and analgesic effects through reversible blockade of neuronal sodium channel. Levobupivacaine can inhibit impulse transmission and conduction in cardiovascular and other tissues, possessing certain cardiac and CNS toxicity. Levobupivacaine is metabolized by hepatic cytochrome P450 (CYP450) enzymes in vivo. Levobupivacaine can also induce ferroptosis by miR-489-3p/SLC7A11 signaling in gastric cancer .

HY-151589

HCVcc-IN-2	Virus Protease	Infection Cancer
HCVcc-IN-2 is a benzothiazole-2-thiophene S-glycoside derivative with antitumor and antiviral activity. HCVcc-IN-2 has high inhibition against the three cell line from CNS cancer (SF-539 and SNB-75), colon cancer (HCT-116), and renal cancer (A498) .

HY-160446

BET-IN-24	Epigenetic Reader Domain	Infection Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
Bet-in-24 (example 2) is a bromodomain and extra-terminal (BET) inhibitor. BET-IN-24 can be used in the study of virology, heart failure, inflammation, central nervous system (CNS) diseases and many cancers

HY-149408

MAOA-IN-1	Monoamine Oxidase	Cancer
MAOA-IN-1 (compound 15) is an orally active MAOA inhibitor with cytotoxicity against prostate cancer cells. MAOA-IN-1 has Caco-2 permeability and lower CNS permeability. MAOA-IN-1 can be further used in the research of anti-cancer and anti-inflammatory indications .

HY-163629

Anticancer agent 224	Others	Cancer
Anticancer agent 224 (Compound 16) is an anticancer agent that can effectively inhibit the growth of central nervous system (CNS), kidney and breast cancer cell, with a GI₅₀ value ranging from 0.6 to 12.8 μM .

HY-153336

CDK-IN-12	CDK	Cancer
CDK-IN-12 (Example 20) is a CDK Inhibitor. CDK-IN-12 Inhibits CDK4/6 with IC₅₀ values less than 20 nM .

HY-145778

AGI-41998	Somatostatin Receptor	Neurological Disease
AGI-41998 is a potent inhibitor of methionine adenosyltransferase 2A (MAT2A). AGI-41998 is a brain-penetrant compound. AGI-41998 has the potential for exploring the effects of SAM modulation in the central nervous system (CNS) and research of cancer disease .

HY-151592

Anticancer agent 91	Antibiotic	Cancer
Anticancer agent 91 is a benzothiazole-2-thiophene S-glycoside derivative with antitumor and antiviral activity. Anticancer agent 91 has high inhibition against the two cell line from CNS cancer (SF-539 and SNB-75) .

HY-145777

AGI-43192	Somatostatin Receptor	Neurological Disease Cancer
AGI-43192 is a potent inhibitor of methionine adenosyltransferase 2A (MAT2A). AGI-43192 is a potent, but limited brain-penetrant compound. AGI-43192 has the potential for exploring the effects of SAM modulation in the central nervous system (CNS) and research of cancer disease .

HY-161084

CSF1R-IN-18	c-Fms	Neurological Disease Cancer
CSF1R-IN-18 (Compdound 16t), para-aniline derivative, is a colony-stimulating factor 1 receptor (CSF1R) inhibitor. CSF1R-IN-18 can be used for the research of cancers, CNS-diseases and bone diseases .

HY-Y0966

Glycine Maximum Cited Publications 7 Publications Verification	Endogenous Metabolite iGluR VEGFR	Neurological Disease
Glycine is an inhibitory neurotransmitter in the CNS and also acts as a co-agonist along with glutamate, facilitating an excitatory potential at the glutaminergic N-methyl-D-aspartic acid (NMDA) receptors. Glycine is orally active. Glycine can be used to study cell protection, cancer, neurological diseases, and angiogenesis .

HY-146230

VEGFR-2-IN-26	VEGFR	Cancer
VEGFR-2-IN-26 (compound 5h) is a highly potent VEGFR-2 inhibitor with an IC₅₀ value of 15.5 nM. VEGFR-2-IN-26 has good antiproliferative activity against the leukemic, non-small lung, CNS, ovarian, renal, prostate and breast cancer cells .

HY-Y0966R

Glycine (Standard)	Endogenous Metabolite iGluR VEGFR	Neurological Disease
Glycine (Standard) is the analytical standard of Glycine. This product is intended for research and analytical applications. Glycine is an inhibitory neurotransmitter in the CNS and also acts as a co-agonist along with glutamate, facilitating an excitatory potential at the glutaminergic N-methyl-D-aspartic acid (NMDA) receptors. Glycine is orally active. Glycine can be used to study cell protection, cancer, neurological diseases, and angiogenesis .

HY-105231

Bryostatin 1 2 Publications Verification	PKC HIV Bacterial	Infection Neurological Disease Inflammation/Immunology Cancer
Bryostatin 1 is a natural macrolide isolated from the bryozoan Bugula neritina and is a potent and central nervous system (CNS)-permeable PKC modulator. Bryostatin 1 binds to the isolated C1 domain of Munc13-1 and the full-length Munc13-1 protein with K_is of 8.07 nM and 0.45 nM, respectively. Bryostatin 1 has anti-cancer, anti-inflammatory, neuroprotective, anti-HIV-1 infection properties .

HY-147405

Tinlorafenib PF-07284890; ARRY-461	Raf	Cancer
Tinlorafenib (PF-07284890) (compound 10) is an orally active BRAF kinase inhibitor, with IC₅₀s of 4.25 and 2.7 nM for BRAF ^V600E/V600K respectively. Tinlorafenib demonstrates CNS penetration and can be used in the research of BRAF-associated malignant and benign tumors of the CNS as well as extracranial malignancies .

HY-147864

c-Fms-IN-12	c-Fms c-Kit Apoptosis	Cancer
c-Fms-IN-12 (Compound 4g) is an FMS kinase inhibitor. c-Fms-IN-12 can also inhibits c-KIT. c-Fms-IN-12 is a potential broad-spectrum anticancer agent against multiple cancer types. c-Fms-IN-12 induces A549 cell apoptosis .

HY-W402682

SXC2023	Others	Neurological Disease Cancer
SXC2023 is an inhibitor for solute carrier family 7 member 11 (SLC7A11). SXC2023 exhibits antitumor efficacy, and ameliorates central nervous system disorder through downregulation of glutamate export .

HY-139090

3-Oxobetulin acetate 28-O-Acetyl-3-Oxobetulin; 3-oxo-28-O-Acetylbetulin	Others	Infection
3-Oxobetulin acetate is a derivative of the cholesterol biosynthesis inhibitor Betulin (HY-N0083). It inhibits the growth of P388 murine lymphocytic leukemia cells (EC₅₀=0.12 μg/mL), as well as human MCF-7 breast, SF-268 CNS, H460 lung, and KM20L2 colon cancer cells (GI₅₀s=8, 10.6, 5.2, and 12.7 μg/mL, respectively), but not BxPC-3 pancreas or DU145 prostate cancer cells (GI₅₀s=>10 μg/mL for both).2 3-Oxobetulin acetate inhibits replication of X4 tropic recombinant HIV (NL4.3-Ren) in MT-2 lymphoblastoid cells (IC₅₀=13.4 μM). It is also active against L. donovani amastigotes when used at a concentration of 50 μM.

HY-158061

Topoisomerase II inhibitor 20	Topoisomerase Apoptosis	Cancer
Topoisomerase II inhibitor 20 (Compound 3e) is a potent topoisomerase II (Topoisomerase II) inhibitor with an IC₅₀ of 0.98 µM. Topoisomerase II inhibitor 20 induces apoptosis and has broad-spectrum anticancer activity .

HY-158061A

Topoisomerase II inhibitor 20 TFA	Topoisomerase Apoptosis	Cancer
Topoisomerase II inhibitor 20 TFA is a potent topoisomerase II inhibitor with IC₅₀ of 0.98 µM. Topoisomerase II inhibitor 20 TFA can induce apoptosis and has broad-spectrum anticancer activity .

HY-169021

JNK-1-IN-3	JNK	Cancer
JNK-1-IN-3 (Compound 9e) is an inhibitor of JNK1 that downregulates JNK1 gene expression and inhibits the protein levels of its phosphorylated form, concurrently reducing the expression of its downstream targets, c-Jun and c-Fos, in tumors while restoring p53 activity. JNK-1-IN-3 exhibits broad-spectrum antiproliferative activity, particularly with high inhibitory activity against renal and breast cancer cell lines, demonstrating both in vivo and in vitro anticancer activity .

Glycine 5+ Cited Publications	Structural Classification Neurological Disease Classification of Application Fields Source classification Amino acids Endogenous metabolite Disease Research Fields	Endogenous Metabolite iGluR VEGFR
Glycine is an inhibitory neurotransmitter in the CNS and also acts as a co-agonist along with glutamate, facilitating an excitatory potential at the glutaminergic N-methyl-D-aspartic acid (NMDA) receptors. Glycine is orally active. Glycine can be used to study cell protection, cancer, neurological diseases, and angiogenesis .

Bryostatin 1 2 Publications Verification	Structural Classification Anti-inflammation/Immunoregulatory Neurological Disease Classification of Application Fields Marine natural products Source classification Other marine organisms Disease Research Infection Macrolide Antibiotics Animals Antibiotics Anticancer Inflammation/Immunology Disease Research Fields	PKC HIV Bacterial
Bryostatin 1 is a natural macrolide isolated from the bryozoan Bugula neritina and is a potent and central nervous system (CNS)-permeable PKC modulator. Bryostatin 1 binds to the isolated C1 domain of Munc13-1 and the full-length Munc13-1 protein with K_is of 8.07 nM and 0.45 nM, respectively. Bryostatin 1 has anti-cancer, anti-inflammatory, neuroprotective, anti-HIV-1 infection properties .

Glycine (Standard)	Structural Classification Human Gut Microbiota Metabolites Microorganisms Ketones, Aldehydes, Acids Source classification Disease markers Endogenous metabolite Cancer	Endogenous Metabolite iGluR VEGFR
Glycine (Standard) is the analytical standard of Glycine. This product is intended for research and analytical applications. Glycine is an inhibitory neurotransmitter in the CNS and also acts as a co-agonist along with glutamate, facilitating an excitatory potential at the glutaminergic N-methyl-D-aspartic acid (NMDA) receptors. Glycine is orally active. Glycine can be used to study cell protection, cancer, neurological diseases, and angiogenesis .

Cat. No.	Product Name		Classification

HY-Y0966

Glycine 5+ Cited Publications		Fillers
Glycine is an inhibitory neurotransmitter in the CNS and also acts as a co-agonist along with glutamate, facilitating an excitatory potential at the glutaminergic N-methyl-D-aspartic acid (NMDA) receptors. Glycine is orally active. Glycine can be used to study cell protection, cancer, neurological diseases, and angiogenesis .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.

CNS cancers

Inhibitors & Agonists

NaturalProducts

Oligonucleotides

Natural
Products